Last reviewed · How we verify
MLN8237
At a glance
| Generic name | MLN8237 |
|---|---|
| Also known as | Alisertib |
| Sponsor | New Approaches to Neuroblastoma Therapy Consortium |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma (PHASE1)
- Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (PHASE2)
- A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) (PHASE2)
- Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer (PHASE2)
- A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer (PHASE2)
- A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer (PHASE2)
- Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer (PHASE1, PHASE2)
- Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MLN8237 CI brief — competitive landscape report
- MLN8237 updates RSS · CI watch RSS
- New Approaches to Neuroblastoma Therapy Consortium portfolio CI